Dr. Scott T. Tagawa on PSMA-targeted agents in prostate cancer
Scott T. Tagawa, MD, discusses the emergence of PSMA-targeted agents in the field of prostate cancer. He draws specific attention to the targeted radioligand therapy 177Lu-PSMA-617 (LuPSMA) and the phase 2 TheraP trial, which showed that LuPSMA had stronger clinical activity with fewer grade 3/4 adverse events compared with cabazitaxel (Jevtana) in patients with metastatic castration-resistant prostate cancer (mCRPC). Subsequent to this interview, it was announced that in the phase 3 VISION trial, adding LuPSMA to best standard of care improved overall survival in patients with progressive PSMA-positive mCRPC.
Tagawa is a professor of Medicine and Urology at Weill Cornell Medicine, and an attending physician at NewYork-Presbyterian/Weill Cornell Medical Center.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
